

Zynlonta[®] 
loncastuximab tesirine
for injection, for intravenous use • 10mg

**Important Safety Information for
Patients taking ZYNLONTA[®]
(loncastuximab tesirine)**

This document is approved by The Executive
Directorate of Pharmacovigilance, at SFDA

**PATIENT
ALERT CARD**

This patient alert card contains important safety information that you need to be aware of during treatment with ZYNLONTA®.

Please always keep this card with you and show this card to any doctor involved in your care.

- Treatment with ZYNLONTA can cause photosensitivity reactions through exposure to direct and indirect sunlight (such as through glass windows in vehicles and public transportation) including:
 - Sunburn-like reactions such as skin peeling and irritation following exposure to light
 - Itchy rash
 - Blistering of skin
 - Darker skin patches
 - Irritation, swelling, pain
- **You must protect skin from exposure to sunlight by wearing sun-protective clothing and/or the use of sunscreen products during the entire treatment period.**
- If you experience any of these skin reactions, you should immediately call your treating doctor or seek emergency medical care.

Information for Healthcare Professionals

Please note that this patient is receiving treatment with ZYNLONTA® (loncastuximab tesirine) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL).

- ZYNLONTA can cause photosensitivity reactions, including sunburn-like reactions such as skin peeling and irritation following exposure to light, itchy rash, blistering of skin, darker skin patches irritation, swelling, pain
- ZYNLONTA should be withheld for severe (Grade 3) cutaneous reactions until resolution
- Dermatologic consultation should be considered
- Contact prescribing doctor (below) as soon as possible
- Report Adverse Events via:
- The National Pharmacovigilance Centre (NPC) Saudi Food and Drug Authority (SFDA):
SFDA call center: 19999
E-mail: npc.drug@sfd.gov.sa
Website: <http://ade.sfd.gov.sa/>
- Swedish Orphan Biovitrum AB (publ):
Email: pv-ksa@sobi.com
- For more information about ZYNLONTA, please refer to the full Summary of Product Characteristics or e-mail: pv-ksa@sobi.com

Contact Details

Patient Name: _____

Hospital where treated: _____

Doctor name: _____

Doctor's telephone number: _____

